GlobeNewsWire · OCS · October 22, 2026

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis

Get the app for more

Explore stock news, insights and company research.